CU24486B1 - Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla - Google Patents

Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla

Info

Publication number
CU24486B1
CU24486B1 CU2016000144A CU20160144A CU24486B1 CU 24486 B1 CU24486 B1 CU 24486B1 CU 2016000144 A CU2016000144 A CU 2016000144A CU 20160144 A CU20160144 A CU 20160144A CU 24486 B1 CU24486 B1 CU 24486B1
Authority
CU
Cuba
Prior art keywords
tablets
prepare
understanding
same
solid dispersion
Prior art date
Application number
CU2016000144A
Other languages
English (en)
Inventor
Ho Taek Im
Yong Ii Kim
Jae Hyun Park
Shanmugam Srinivasan
Jong Soo Woo
Young Su Yoon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54240734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24486(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CU24486B1 publication Critical patent/CU24486B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención provee una dispersión sólida amorfa que comprende un taxano o una sal del mismo aceptable desde el punto de vista farmacéutico, un polímero aceptable desde el punto de vista farmacéutico, y un agente tensoactivo aceptable desde el punto de vista farmacéutico, Ia cual tiene solubilidad mejorada. También se provee un método para Ia preparación de Ia dispersión sólida. La presente invención también provee una tableta que tiene buena solubilidad, biodisponibilidad y estabilidad, que comprende Ia dispersión sólida amorfa, un excipiente intragranular, y un excipiente extragranular.</p>
CU2016000144A 2014-03-31 2015-03-20 Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla CU24486B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/KR2014/002734 WO2015152433A1 (en) 2014-03-31 2014-03-31 Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
PCT/KR2015/002756 WO2015152544A1 (en) 2014-03-31 2015-03-20 Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same

Publications (1)

Publication Number Publication Date
CU24486B1 true CU24486B1 (es) 2020-11-30

Family

ID=54240734

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000144A CU24486B1 (es) 2014-03-31 2015-03-20 Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla

Country Status (34)

Country Link
US (1) US9867801B2 (es)
EP (1) EP3125872B1 (es)
JP (1) JP6539675B2 (es)
KR (1) KR101851571B1 (es)
CN (1) CN106255496B (es)
AR (1) AR099886A1 (es)
AU (1) AU2015242738B2 (es)
BR (1) BR112016022528B1 (es)
CA (1) CA2944438C (es)
CL (1) CL2016002441A1 (es)
CU (1) CU24486B1 (es)
DK (1) DK3125872T3 (es)
DO (1) DOP2016000262A (es)
ES (1) ES2748686T3 (es)
GT (1) GT201600208A (es)
HU (1) HUE046616T2 (es)
IL (1) IL247977B (es)
LT (1) LT3125872T (es)
MA (1) MA39361B1 (es)
MX (1) MX373189B (es)
MY (1) MY175387A (es)
PE (1) PE20161477A1 (es)
PH (1) PH12016501825B1 (es)
PL (1) PL3125872T3 (es)
PT (1) PT3125872T (es)
PY (1) PY1513631A (es)
RU (1) RU2684632C2 (es)
SA (1) SA516371952B1 (es)
SG (1) SG11201607456RA (es)
SI (1) SI3125872T1 (es)
TW (1) TWI706793B (es)
UA (1) UA117610C2 (es)
UY (1) UY36055A (es)
WO (2) WO2015152433A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms
WO2017196712A1 (en) * 2016-05-09 2017-11-16 Dispersol Technologies, Llc Improved drug formulations
CN110742895A (zh) * 2017-03-30 2020-02-04 复旦大学附属中山医院 Fxr激动剂在制备治疗脂肪肉瘤药物中的用途
TW202435853A (zh) * 2017-10-06 2024-09-16 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法
US20190142756A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Drug formulations
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法
CN110105368B (zh) * 2019-05-09 2022-01-07 上海大学 去氧紫杉烷类似物及其制备方法
CA3152401A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
PL4069199T3 (pl) 2019-12-02 2024-06-10 Astrazeneca Ab Stałe Formulacje Farmaceutyczne 6-(2-Chloro-6-Metylopirydyn-4-Ylo)-5-(4-Fluorofenylo)-1,2,4-Triazyno-3-Aminy
WO2021177930A1 (en) * 2020-03-06 2021-09-10 Vyshnevskyy Ihor Anatoliyovych Pharmaceutical composition with increased solubility of gesperidine and method of its preparation
JP7823036B2 (ja) 2020-10-07 2026-03-03 ヘルス ホープ ファーマ エイチケー リミテッド アセトアミド－フェニルテトラゾール誘導体およびその使用方法
JP2024525206A (ja) * 2021-06-23 2024-07-10 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の医薬組成物
US20250242031A1 (en) * 2022-02-14 2025-07-31 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions
KR20240151747A (ko) * 2022-03-08 2024-10-18 (주)씨앤팜 도세탁셀 또는 이의 약학적으로 허용 가능한 염을 포함하는 약학적 조성물 및 이의 제조방법
CN115429766B (zh) * 2022-09-08 2023-10-27 江苏集萃新型药物制剂技术研究所有限公司 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502500A (en) 1997-06-27 2002-03-28 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
CN1840196A (zh) * 2006-01-27 2006-10-04 无锡杰西医药科技有限公司 一种适用于难溶性药物的分散剂
WO2007073389A1 (en) 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
CA2696622C (en) * 2007-08-24 2016-07-19 Stichting Het Nederlands Kanker Instituut Compositions for the treatment of neoplastic diseases
WO2009092601A1 (en) * 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
CN101632630A (zh) * 2008-07-24 2010-01-27 北京诺美医药科技有限公司 一种普罗布考固体分散体
EP2328555A2 (en) * 2008-08-22 2011-06-08 Slotervaart Participaties BV Compositions for the treatment of neoplastic diseases
JP5751868B2 (ja) * 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
CN102357075A (zh) * 2011-09-30 2012-02-22 武汉平华生物医药科技有限公司 一种多西他赛纳米制剂及其制备方法

Also Published As

Publication number Publication date
GT201600208A (es) 2018-11-27
DOP2016000262A (es) 2017-01-15
IL247977B (en) 2019-09-26
RU2684632C2 (ru) 2019-04-11
PY1513631A (es) 2017-10-02
KR101851571B1 (ko) 2018-04-26
EP3125872A4 (en) 2017-10-11
MX373189B (es) 2020-04-21
TW201620506A (zh) 2016-06-16
WO2015152433A1 (en) 2015-10-08
PL3125872T3 (pl) 2020-03-31
PE20161477A1 (es) 2017-01-29
RU2016136636A3 (es) 2018-09-25
MA39361A1 (fr) 2017-06-30
KR20160124904A (ko) 2016-10-28
AU2015242738B2 (en) 2019-09-26
ES2748686T3 (es) 2020-03-17
SI3125872T1 (sl) 2019-11-29
BR112016022528A2 (pt) 2017-08-15
AR099886A1 (es) 2016-08-24
WO2015152544A1 (en) 2015-10-08
SA516371952B1 (ar) 2020-12-07
US9867801B2 (en) 2018-01-16
RU2016136636A (ru) 2018-05-03
CN106255496B (zh) 2019-10-18
CN106255496A (zh) 2016-12-21
CA2944438A1 (en) 2015-10-08
NZ723991A (en) 2021-01-29
PH12016501825A1 (en) 2016-11-07
IL247977A0 (en) 2016-11-30
JP6539675B2 (ja) 2019-07-03
JP2017509653A (ja) 2017-04-06
SG11201607456RA (en) 2016-10-28
DK3125872T3 (da) 2019-10-14
AU2015242738A1 (en) 2016-09-22
BR112016022528B1 (pt) 2023-04-11
HUE046616T2 (hu) 2020-03-30
CL2016002441A1 (es) 2017-02-17
UA117610C2 (uk) 2018-08-27
UY36055A (es) 2016-09-30
PH12016501825B1 (en) 2021-06-23
MA39361B1 (fr) 2018-06-29
CA2944438C (en) 2021-10-26
US20170112799A1 (en) 2017-04-27
TWI706793B (zh) 2020-10-11
EP3125872A1 (en) 2017-02-08
EP3125872B1 (en) 2019-08-14
LT3125872T (lt) 2019-10-10
PT3125872T (pt) 2019-10-24
MY175387A (en) 2020-06-23
MX2016012596A (es) 2017-01-09

Similar Documents

Publication Publication Date Title
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
EP3302426A4 (en) D2o stabilized pharmaceutical formulations
MA39986A (fr) Dérivés de purine en tant qu&#39;inhibiteurs de cd73 pour le traitement du cancer
PH12016501841A1 (en) Immunosuppressant formulation
EP3389628A4 (en) PHARMACEUTICAL FORMULATIONS OF MOUSE CHEESE TABLETS
EP3193854A4 (en) Eutectic formulations of cyclobenzaprine hydrochloride
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
EP3471708A4 (en) STABLE, ORAL-DEGRADATING PHARMACEUTICAL COMPOSITIONS
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
EP3240532A4 (en) Processes for producing pharmaceutical excipients from lignocellulosic biomass, and pharmaceutical excipients obtained therefrom
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
BR112017019364A2 (pt) dispersões sólidas
CL2017000026A1 (es) Formas de dosificación farmacéutica
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
IL264851B (en) Pure heptasulfated disaccharides having improved oral bioavailability
PE20181019A1 (es) Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo
MX2015011152A (es) Composicion farmaceutica de omeprazol-bicarbonato de sodio para integrar una capsula, para el tratamiento de alopatias relacionadas con la acidez gastrica.
TR201720510A2 (tr) Orally disintegrating tablet formulations of ivabradine
IN2014MU00077A (es)
ECSP16086746A (es) Formulación inmunosupresora